Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ABT, MDT collaborate on CGM/insulin-delivery system:
https://finance.yahoo.com/news/abbott-enters-global-partnership-connect-120000316.html
Abbott today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.
The integration of Abbott's CGM sensor with Medtronic's AID algorithms will enable automatic adjustments of insulin to keep glucose in range. The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.
Cramer is still bullish...great qtr...infant death law suit is just a bunch of BS and not new...I'm not selling...just one bad day IMO
ABT reports 2Q24 results—raises 2024 guidance slightly—for the second consecutive quarter, stock sells off because ABT didn’t raise 2024 guidance to a larger degree:
https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance
2024 guidance for organic sales growth excluding COVID diagnostics is now 9.5-10%, up from the prior guidance of 8.5-10% given three months ago.
2024 guidance for non-GAAP EPS (which excludes FX and restructuring costs) is now $4.61-4.70, up from the prior guidance of $4.55-4.70 given three months ago.
2Q24 non-GAAP and GAAP EPS were $1.14 and $0.74, respectively, versus $1.08 and $0.78 in 2Q23. These YOY comparisons were adversely affected by a 56% decline in COVID-diagnostic sales, which were $102M in 2Q24 in 2Q24 vs $230M in 2Q23.
2Q24 FreeStyle Libre sales were $1.6B, +20% YoY in constant currency. FreeStyle Libre is the largest-selling medical device, ever, from any company.
Please see #msg-174774187 for a breakdown of ABT’s 2Q24 sales by business segment.
Way undervalued here
Roche enters_the CGM market—in EU only—(for now):
https://www.globenewswire.com/news-release/2024/07/09/2910036/0/en/Roche-receives-CE-Mark-for-its-AI-enabled-continuous-glucose-monitoring-solution-offering-critical-predictions-to-people-living-with-diabetes.html
This may explain why ABT and DXCM are down 2%-3% this week.
ABT launches over-the-counter CGMs:
https://finance.yahoo.com/news/abbott-receives-u-fda-clearance-120000542.html
• Abbott's consumer biowearable, Lingo, is designed for general consumers who are looking to improve their overall health and wellness
• Libre Rio is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications
• Both products are based on FreeStyle Libre sensing technology, the world's most widely used1 continuous glucose monitoring (CGM) systems, pioneered by Abbott and used by about 6 million people globally
ABT reports 1Q24 results—raises 2024 guidance slightly—stock sells off because ABT didn’t raise 2024 guidance to a larger degree:
https://abbott.mediaroom.com/2024-04-17-Abbott-Reports-First-Quarter-2024-Results-and-Raises-Midpoint-of-Full-Year-Guidance-Ranges
2024 guidance for organic sales growth excluding COVID diagnostics is now 8.5-10%, up from the prior guidance of 8-10%.
2024 guidance for non-GAAP EPS (which excludes FX and restructuring costs) is now $4.55-$4.70, up from the prior guidance of $4.50-4.70.
1Q24 non-GAAP and GAAP EPS were $0.98 and $0.70, respectively, versus $1.03 and $0.59 in 1Q23. The YoY decline in non-GAAP EPS was due to lower sales of COVID diagnostics, which were $204M in 1Q24 vs $730M in 1Q23.
4Q23 FreeStyle Libre sales were $1.5B, +23% YoY in constant currency. FreeStyle Libre is the largest-selling medical device, ever, from any company.
Please see #msg-174255202 for a breakdown of ABT’s 1Q24 sales by business segment.
FDA approves ABT’s TriClip device for repair tricuspid heart valve:
https://finance.yahoo.com/news/abbott-receives-fda-approval-triclip-130000245.html
EW is the only other company with a similar device.
FDA clears ABT’s 15-minute test for TBI/concussion:
https://finance.yahoo.com/news/abbott-receives-fda-clearance-whole-130000849.html
Note: This is not the hand-held diagnostic ABT is developing to give TBI results from a simple finger prick (#msg-172397644).
ABT launches adult-nutrition product_to_maintain muscle mass_for_people_on_weight-loss_drugs:
https://finance.yahoo.com/news/abbott-launches-protality-brand-support-140000191.html
Abbott, a global leader in science-based nutrition, announced today the launch of its new PROTALITY brand. The high-protein nutrition shake is the first product in this line to support the growing number of adults interested in pursuing weight loss while maintaining muscle mass and good nutrition.
…To preserve muscle mass during weight loss, research shows adults may need at least 50 percent more protein than the Recommended Dietary Allowance (RDA). High protein consumption can also support weight loss maintenance.
ABT 4Q23 Results by Business Segment
61% of overall corporate sales were ex-US.
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 43% +17%
Nutrition 20% +13%
Diagnostics 25% -22%†
Pharmaceuticals‡ 12% +9%
ABT reports 4Q23 results—issues 2024 guidance:
https://abbott.mediaroom.com/2024-01-24-Abbott-Reports-Fourth-Quarter-and-Full-Year-2023-Results-Issues-2024-Financial-Outlook
2024 guidance for organic sales growth excluding COVID diagnostics is 8-10%.
2024 guidance for non-GAAP EPS (which excludes FX and restructuring costs) is $4.50-4.70, -12-16% vs $5.34 in 2023. 2024 guidance for GAAP EPS is $3.20-3.40, -13-18% vs $3.91 in 2023. The expected YoY declines in non-GAAP and GAAP EPS are due to lower expected sales of COVID diagnostics, which were $1.59B in 2023.
4Q23 non-GAAP and GAAP EPS were $1.19 and $0.91, respectively, versus $1.03 and $0.59 in 4Q22. The YoY growth in EPS came despite sharply lower sales of COVID diagnostics, which were $288M in 4Q23 vs $1.07B in 4Q22.
4Q23 FreeStyle Libre sales were $1.4B, +26% YoY. FreeStyle Libre is the largest-selling medical device, ever, from any company.
Please see #msg-173691063 for a breakdown of ABT’s 4Q23 sales by business segment.
ABT increases dividend for 52nd(!) consecutive year:
https://finance.yahoo.com/news/abbott-increases-quarterly-dividend-52nd-162500327.html
The new annualized payout is $2.20, +7.8% from $2.04 in 2023, and +17% from $1.88 in 2022. At the current share price ($107.29), the new annualized payout is a yield of 2.1%.
GLP-1 effect on medical-device companies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173203785
ABT reports 3Q23 results—increases_midpoint_of_ 2023_EPS_ guidance:
https://abbott.mediaroom.com/2023-10-18-Abbott-Reports-Third-Quarter-2023-Results-and-Raises-Midpoint-of-Full-Year-EPS-Guidance-Range
ABT continues to expect 2023 organic sales growth (excluding COVID-diagnostic sales) in the low double digits. 3Q23 organic sales growth was 13.5%.
3Q23 GAAP and non-GAAP EPS were $0.82 and $1.14, respectively, flat versus $0.81 and $1.15 in 3Q22. The YoY flatness was due to sharply lower COVID-diagnostics revenue: $305M in 3Q23 vs $1.67B in 3Q22. (ABT now expects 2023 COVID-diagnostics sales of $1.5B, which implies ~$200M for 4Q23.)
ABT raised the midpoint and tightened the ranges for 2023 EPS guidance. The new guidance is: GAAP $3.14-3.18 (from the prior range of $3.02-3.22); and non-GAAP $4.42-4.46 (from the prior range of $4.30-4.50).
3Q23 FreeStyle Libre sales were $1.4B, +29% YoY. FreeStyle Libre is already the largest-selling medical device, ever, from any company.
Please see #msg-173045466 for a breakdown of ABT’s 3Q23 sales by business segment.
ABT inks deal to sell biosimilars in emerging markets:
https://www.prnewswire.com/news-releases/abbott-broadens-access-to-cutting-edge-biosimilars-in-key-emerging-markets-301932956.html
This is a good fit for ABT’s “branded generics” business, which sells off-patent small-molecule drugs in emerging markets and comprises 13% of ABT’s overall sales (#msg-172393746).
ABT acquires—(private)—Bigfoot Biomedical for undisclosed price:
https://finance.yahoo.com/news/abbott-acquire-bigfoot-biomedical-furthering-203000744.html
Abbott and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
…Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data along with healthcare provider instructions to provide insulin dosing recommendations. The dosing recommendations are displayed on the pen cap's digital screen to help people know how much insulin to take.
The Bigfoot Unity system exclusively works with Abbott's world-leading FreeStyle Libre technology and includes a customer smartphone app connected to a cloud-based online portal used by healthcare providers to support their patients, including through remote care. The system works with FreeStyle Libre 2 sensors and all major brands of both long-acting (basal) and rapid-acting (bolus) disposable insulin pens offered in the United States.
Great report!!
That's quite an understatement!
Check out #msg-172397644.
ABT 2Q23 Results by Business Segment
62% of overall corporate sales were ex-US.
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 43% +14%
Diagnostics 23% -46%†
Nutrition 21% +10%
Branded generics 13% +13%
ABT reports 2Q23 results—increases 2023 guidance_for_organic_sales_growth:
https://abbott.mediaroom.com/2023-07-20-Abbott-Reports-Second-Quarter-2023-Results-Increases-Outlook-For-Underlying-Base-Business
2Q23 GAAP and non-GAAP EPS were $0.78 and $1.08, respectively, down from $1.14 and $1.43 in 2Q22. The YoY declines were due to sharply lower COVID-diagnostics revenue: $263M in 1Q23 vs $2.3B in 2Q22. (ABT now expects 2023 COVID-diagnostics sales of $1.3B, which implies ~$300M for 2H23.)
2Q23 FreeStyle Libre sales were $1.3B, +25% YoY. FreeStyle Libre is already the largest-selling medical device, ever, from any company.
ABT’s full-year 2023 guidance is essentially unchanged from three months ago: GAAP EPS of $3.02-3.22; and non-GAAP EPS (which excludes restructuring costs and FX) of $4.30-4.50. ABT was able to retain the pre-existing guidance despite the reduced forecast for 2H23 COVID diagnostics because the 2H23 outlook for ABT’s organic (non-COVID) business has improved.
Specifically, ABT now expects 2023 organic sales growth in the low double digits, an upgrade from the guidance three months ago of “at least high dingle digits.” 2Q23 organic sales growth was 11.5%, up from 10% in 1Q23.
Please see #msg-172393746 for a breakdown of ABT’s 2Q23 sales by business segment.
Medical-device stocks (including ABT) are strong today, while health-insurance stocks (e.g. HUM) are weak. Somebody apparently just realized that elective-procedure volumes are back to pre-pandemic levels and growing.
ABT—This looks like a meritless lawsuit:
https://finance.yahoo.com/news/1-abbott-labs-sued-over-213744088.html
Nevertheless, crazier lawsuits have succeeded, so an investor can’t take anything for granted when it comes to tort exposure.
ABT 1Q23 Results by Business Segment
60% of overall corporate sales were ex-US.
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 40% +12%
Diagnostics 28% -47%†
Nutrition 20% +10%‡
Branded generics 12% +11%
ABT reports 1Q23 results—slightly increases 2023 guidance:
https://abbott.mediaroom.com/2023-04-19-Abbott-Reports-First-Quarter-2023-Results-Increases-Outlook-For-Underlying-Base-Business
1Q23 GAAP and non-GAAP EPS were $0.75 and $1.03, respectively, down from $1.37 and $1.73 in 1Q22. The reason for the decline is, of course, falling COVID-diagnostics revenue, which was $730M in 1Q23 vs $3.3B in 1Q22.
1Q23 FreeStyle Libre sales were $1.2B, +9% QoQ and +20% YoY (+50% YoY in the US).
ABT reiterated full-year 2023 guidance from three months ago: GAAP EPS of $3.05-3.25; and non-GAAP EPS (which excludes restructuring costs and FX) of $4.30-4.50.
ABT now expects 2023 COVID-diagnostics sales of $1.5B (i.e. $770M for the remaining nine months of the year, only slightly above the $730M logged in 1Q23).
Excluding COVID diagnostics, ABT expect 2023 organic sales growth of “at least high dingle digits,” which is a subtle word change from three months ago when the phrase “at least” was not in the guidance language. In 1Q23, organic sales growth excluding COVID diagnostics was 10.0%.
The stock is +7% as I’m typing. Investors are evidently impressed with ABT’s ability to maintain—and subtly increase (see above)—2023 guidance despite the steep falloff in COVID sales.
FreeStyle Libre gets expanded Medicare coverage:
https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-continuous-glucose-monitoring-systems-obtain-significantly-expanded-coverage-for-medicare-beneficiaries-301798550.html
FDA clears ABT's standalone glucose reader from FreestyleLibre:
https://finance.yahoo.com/news/fda-clears-reader-abbotts-freestyle-130000671.html
Abbott today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet glucose sensor. With the FDA's clearance of a standalone reader, Abbott is working to get the FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible.
FDA enables_integration_of FreeStyle Libre with automated insulin delivery systems:
https://finance.yahoo.com/news/u-fda-clears-abbotts-freestyle-120000948.html
Abbott today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.
…AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.
Abbott is working with leading insulin pump manufacturers to integrate their systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors as soon as possible. The company is partnering with Insulet and Tandem for future integrations in multiple countries, including the U.S. Outside the U.S., Abbott's FreeStyle Libre 3 sensor is already authorized to work with the mylife Loop solution from Ypsomed and CamDiab in Germany, with additional launches in the UK, Switzerland and the Netherlands planned for the first half of this year.
ABT TriClip (tricuspid-value clip) highlighted_at ACC…
NYT story (Gina Kolata):
https://www.nytimes.com/2023/03/04/health/tricuspid-valve-clip-leakage.html
ABT’s own PR:
https://finance.yahoo.com/news/data-show-superiority-abbotts-triclip-154100517.html
ABT acquires CSII for $20/sh cash—a 50% premium to today’s closing price:
• Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow
• CSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease
ABT reports 4Q22 results—issues 2023 guidance:
https://abbott.mediaroom.com/2023-01-25-Abbott-Reports-Fourth-Quarter-and-Full-Year-2022-Results-Issues-2023-Financial-Outlook
2023 GAAP EPS guidance is $3.05-3.25, -19% YoY at the midpoint of the range. 2023 non-GAAP EPS guidance (which excludes restructuring costs and FX) is $4.30-4.50, -18% YoY at the midpoint of the range.
The reason 2023 guidance is below 2022 results for both GAAP and non-GAAP EPS is, of course, declining COVID-diagnostics revenue. In 2022, ABT sold $8.4B of COVID diagnostics, but 2023 guidance is only $2.0B as testing volume has fallen off rapidly from the peak of the pandemic.
On a positive note, 4Q22 Freestyle Libre sales were $1.1B, including a 40% YoY increase in the US market.
Excluding COVID diagnostics, ABT expects 2023 organic sales growth in the high dingle digits.
ABT CEO at JPM: “Libre will become a $10B product in the next 5 years.”
I.e., Libre is almost certain to be the biggest-selling medical device, ever.
ABT increases dividend for 51st(!) consecutive year:
https://finance.yahoo.com/news/abbott-increases-quarterly-dividend-marking-154800419.html
The new annualized payout is $2.04, up from $1.88 (an 8.5% bump). At the current share price ($107.84), the new payout is a yield of 1.9%.
Yes sir Dew, I was nit taking a shot at you Thought everyone already knew this and was already priced in. Then consider guidance. Should not be down like this.
From my post earlier today:
The stock is trading down this morning because 3Q22 sales were hit by three factors: 1) The recall of infant formula produced at the Sturgis, MI plant; 2) declining COVID diagnostics ($1.7B in 3Q22 vs $2.3B in 2Q22); and 3) the strong US dollar.
And yet its selling off like crazy
ABT 3Q22 Results by Business Segment
3Q22 COVID-diagnostics sales were $1.7B, 46% of 3Q22 diagnostics sales.
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 35% +6%
Diagnostics 35% -1%
Nutrition 17% -10%
Drugs† 13% +12%
Followers
|
42
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
813
|
Created
|
07/06/06
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |